Clinically, this subset of breast tumors is defined by high level expression of HER2 on the plasma membrane of >10% of the cells within a tumor, assessed by immunohistochemistry, and/or by amplification of the ERBB2 gene, as evidenced by fluorescent in situ hybridization. The gene discussed is ERBB2; the disease is neoplasm.